Novartis jettisons ph. 1 cancer candidate after 0% efficacy
Novartis has jettisoned an anti-cancer protein from its pipeline after the molecule failed to shrink tumors in 30…
Top pharmaceutical companies for innovation: Roche, AbbVie, Novartis, and more
The 2020 Pharmaceutical Invention and Innovation Indices, compiled by IDEA Pharma, were generated prior to the unfolding COVID-19…
UBS Upgrades Biogen to Buy With a $225 Target: Are the Next 12 Months a Pipeline Catalyst Parade?
Biogen (BIIB) stock got an upgrade to Buy from UBS with a $225 price target, citing upcoming BIIB080…